Roche has appointed Dr Harsukh Parmar as Head of Translational and Experimental Medicine (TM) of its Inflammation Discovery and Translational Area (DTA).
Dr Parmar will be responsible for the strategy and implementation of early clinical progress in Inflammation as well as collaborating with Discovery and Clinical Development to ensure high quality of compounds used throughout drug production.
Dr Jacques Banchereau, Head of the Inflammation and Virology Discovery and Translational Areas, said that Harsukh is recognised as “an expert in respiratory, inflammation, immunology and oncology, and possesses the right combination of experience for this pivotal position”.
Dr Parmar joins Roche from AstraZeneca in the UK, where he worked as Early Development Director, Vice President and Global Head of Early Clinical Development in the Respiratory and Inflammation Therapeutic Area. He also previously served at Roche as Global Clinical Science Leader and Director in Oncology, Immunology, Virology and Transplantation.
“Having previously worked for Roche and recognising the rich heritage of innovation that has come from the pharma business in small molecules and biologics, I was excited to rejoin a company that has been a leader in many of its respective fields,” said Dr Parmar.